Enterprise Value
337.4M
Cash
176.3M
Avg Qtr Burn
-11.64M
Short % of Float
25.97%
Insider Ownership
8.67%
Institutional Own.
71.96%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CABA-201 (4-1BB CD19-CAR T) Details Systemic lupus erythematosus, Lupus nephritis | Phase 1/2 Data readout | |
CABA-201 (4-1BB CD19-CAR T) Details Immune-mediated necrotizing myopathy, Anti-synthetase syndrome, Idiopathic inflammatory myopathy / myositis, Dermatomyositis | Phase 1/2 Data readout | |
CABA-201 (4-1BB CD19-CAR T) Details Myasthenia gravis | Phase 1/2 Initiation | |
CABA-201 (4-1BB CD19-CAR T) Details Systemic sclerosis | Phase 1/2 Initiation | |
MuSK-CAART Details Myasthenia gravis, Autoimmune disease | Phase 1 Data readout | |
DSG3-CAART Details Mucosal Pemphigus Vulgaris | Phase 1 Data readout |